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INTRODUCTION
Despite the improvements in surgical techniques, immuno-
suppression, and antimicrobial agents, infection remains one
of the important complications after solid organ transplantation
(1-3). The incidence of infectious complications is especially
high in patients who undergo liver tansplantation (LT), because
patients requiring this procedure tend to be in poorer condi-
tion and the combination of the surgical procedure and the
use of immunosuppression after LT is associated with a higher
risk of infection than after transplantation of other solid organs. 
Children who undergo organ transplantation have a higher
incidence of viral infection and a poorer outcome than adults,
due to the high incidence of primary infection, especially with
cytomegalovirus (CMV) (4) and Epstein-Barr virus (EBV)
(5), in younger seronegative patients. Therefore studies of
infection after LT in children differ markedly from studies
in adults. LT in children more frequently involves living than
cadaveric donor tissue, because of the scarcity of size-matched
deceased donors for small children. However, studies of infec-
tious complications after living donor liver transplantation
(LDLT) in children are relatively rare (6-9). 
Although LDLT was initially developed to overcome the
shortage of donor livers for children (10), it has now been
adapted for adults in areas with donor shortages (11). Ideal-
ly LDLT is associated with the improvement of graft and pati-
ent survival because the condition of these patients is better,
due to shorter waiting time, use of elective surgery, and bet-
ter graft viability due to short ischemic time (12).
Studies of infection following pediatric LDLT are necessary
to improve management after LT and to provide better pati-
ent outcomes. We therefore investigated infectious compli-
cations after pediatric LDLT.
MATERIALS AND METHODS
Patients
We enrolled 95 children (38 boys, 57 girls) who underwent
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Infections after Living Donor Liver Transplantation in Children
The aim of this study was to evaluate the infectious complications after living donor
liver transplantation (LDLT) in children. We enrolled 95 children (38 boys and 57
girls) who underwent LDLT from 1994 to 2004. The median age was 22 months
(range, 6 months to 15 yr). We retrospectively investigated the proven episodes of
bacterial, viral, and fungal infection. There occurred 150 infections in 67 (70%) of
95 patients (1.49 infections/patient); 74 in 43 patients were bacterial, 2 in 2 were
fungal, and 74 in 42 were viral. The most common sites of bacterial infection were
the bloodstream (33%) and abdomen (25%). Most of the bacterial infections occurred
within the first month after LDLT. Bacterial and fungal infections did not result in any
deaths. The most common causes of viral infection were Epstein-Barr virus in 37
patients and cytomegalovirus in 18. Seven of the 14 deaths after LDLT were asso-
ciated with viral infection. Our study suggests that infection is one of the important
causes of morbidity and mortality after LDLT. Especially careful monitoring and man-
agement of viral infections is crucial for improving the outcome of LDLT in children.
Key Words : Infection; Liver Transplantation; Living Donors; Child
Received : 14 July 2009
Accepted : 27 July 2009
ⓒ 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.LDLT at the Asan Medical Center from 1994 to 2004. Medi-
an age of the patients at LT was 22 months (range, 6 months
to 15 yr). Sixty children underwent LDLT for biliary atresia,
15 for acute liver failure, 7 for Wilson disease, 3 for unex-
plained liver cirrhosis, 2 for progressive familial intrahepatic
cholestasis, 2 for ornithine transcarbamylase deficiency, and
6 for other causes (Table 1). 
Perioperative management
The left lateral segment or left lobe grafts of the liver were
implanted into most of the children according to routine pro-
cedures (13). Those patients were managed in the intensive
care unit for 5 to 14 days postoperatively, including isolation,
and were usually discharged from the hospital without compli-
cations 3 to 4 weeks after surgery. For 2 days prior to surgery,
all patients underwent selective bowel decontamination with
oral neomycin, erythromycin, and mycostatin. All patients
received intravenous prophylactic antibiotics with Unasyn
�
(ampicillin plus sulbactam, 150 mg/kg/day) and cefotaxime
(100 mg/kg/day) before surgery and for 5 days postoperatively.
All patients received CMV prophylaxis with intravenous gan-
ciclovir (6 mg/kg/day) for 14 days after surgery, followed by
oral acyclovir (40 mg/kg/day) for 6 months. All patients also
received mycostatin (500,000 U/day) for antifungal prophylax-
is and sulfamethoxazole-trimethoprim (8 mL/kg/day for 3 days)
for Pneumocystis jiroveci prophylaxis for 6 months after surgery.
Immunosuppression
Maintenance immunosuppression regimens consisted of a
triple cyclosporine-based drug regimen, which included aza-
thioprine and prednisolone (PD) for the first 11 patients; all
other patients received a dual tacrolimus-based drug regimen
that included PD. Cyclosporine was administered intrave-
nously, and then orally, with the dosages adjusted to main-
tain trough level at 250-350 ng/mL for the first 6 months,
100-250 ng/mL for the next 6 months and 50-100 ng/mL
thereafter. Oral tacrolimus was administered, with the dosages
adjusted to maintain trough level at 10-15 ng/mL for the
first 2 weeks, 5-10 ng/mL for the next 2 months, and 5 ng/
mL thereafter. Methyl PD was administered at a dosage of
10 mg/kg intraoperatively, and tapered to 0.3 mg/kg on day
7. Beginning on day 8, all patients were administered oral
PD, starting at a dosage of 0.3 mg/kg/day. In patients given
the cyclosporine regimen, PD was changed into on alternate
days indefinitely and in patients given the tacrolimus regi-
men, PD was tapered during the next 3-6 months for pati-
ents. All patients given the cyclosporine regimen were also
administered azathioprine for 3 months, at an average dosage
of 1 mg/kg/day. Children who experienced acute rejection
were given methylprednisolone pulse therapy; if there was
no response, daclizumab, azathioprine, and mycophenolate
mofetil were administered according to response. 
Diagnosis of infection
Bacterial and fungal infections were diagnosed based on
their clinical manifestations and the isolation of organisms.
Viral infections were diagnosed based on clinical manifesta-
tions, serology, the shell vial antigen method for CMV, immu-
nohistochemical staining for CMV, EBV-encoded RNA in
situ hybridization, and, since 2003, quantitative polymerase-
chain reaction for CMV and EBV load monitoring. Primary
infection was diagnosed when seroconversion occurred, from
negative preoperatively to positive postoperatively. Reacti-
vation was diagnosed when there was a four-fold increase in
titer or anti-IgM antibody was detected. Hepatitis B virus
infection was not analyzed in this study.
RESULTS
Overall incidence of infections
We observed 150 infections in 67 of the 95 (70%) patients
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Underlying causes n=95 (%)
Biliary atresia 60 (63)
Fulminant hepatic failure 15 (16)
Wilson disease 7 (7)
Liver cirrhosis  3 (3)
Progressive familial intrahepatic cholestasis  2 (2)
Ornithine transcarbamylase deficiency 2 (2)
Alagille syndrome 1 (1)
Biliary duct stricture 1 (1)
Citrullinemia 1 (1)
Neonatal hepatitis 1 (1)
Protein C deficiency 1 (1)
Intrahepatic bile duct paucity 1 (1)
Table 1. Underlying causes of pediatric LDLT at Asan Medical
Center from 1994 to 2004
Pathogens
1-6 months >6 months <1 months Total
Post-transplantation period
Bacterial 42 31 1 74
Viral 14 31 29 74
CMV 4 13 1 18
EBV 6 13 18 37
Others 4 5 10 19
Fungal 2 0 0 2
Total 58 (39%)  62 (41%)  30 (20%)  150 (100%)
Table 2. Incidence and timing of infections after pediatric LDLT
at Asan Medical Center from 1994 to 2004
LDLT, living donor liver transplantation.  
LDLT, living donor liver transplantation; CMV, cytomegalovirus; EBV,
Epstein-Barr virus.  (1.57 infections per patient); 74 infections in 43 patients were
bacterial, 2 in 2 patients were fungal, and 66 in 42 patients
were viral. Most of the bacterial and fungal infections occurred
within 1 month after LDLT, whereas most viral infections
occurred after 1 month (Table 2).
Bacterial infections
We observed 74 episodes of bacterial infection in 43 chil-
dren, 42 (57%) within 1 month after LDLT and 73 (99%)
within 6 months. Of the 74 infections, 41 (55%) were with
Gram negative organisms, 32 (44%) were with Gram posi-
tive organisms, and 1 (1%) was with an anaerobic organism.
The most common bacterial pathogens were Klebsiella pneu-
moniae (16%), Pseudomonas aeruginosa (16%), coagulase-nega-
tive Staphylococcus (15%), and Enterobacter faecium (10%) (Table
3). The most common clinical manifestations of bacterial infec-
tion were septicemia (33%), peritonitis (25%), and cholan-
gitis (21%) (Table 4).
Fungal and parasitic infections
Only two episodes of fungal infection, in 2 patients, were
documented. Both patients had a history of vancomycin treat-
ment and both organisms were isolated from ascites. No epi-
sodes of parasitic infection were observed.
Viral infections
Seventy four episodes of viral infection occurred in 42 pati-
ents, including 37 episodes of EBV infection, 18 of CMV,
10 of rotavirus, 2 of respiratory syncytial virus (RSV), 2 of
enterovirus, 2 of rubella virus, 1 of influenza virus, 1 of her-
pes simplex virus and one of parainfluenza virus (Table 5).
Of the 18 episodes of CMV infection, 14 were primary infec-
tions and 4 were reactivations. Of the involved patients, 9
had hepatitis, 2 had gastroenteritis, 2 had pneumonia, and
7 were asymptomatic. Most of the infection occurred bet-
ween one to 6 months. Thirty seven patients experienced
EBV infection; 11 were primary infections and 26 were reac-
tivations. Of these patients, 9 had posttransplant lymphopro-
liferative disease (PTLD), 21 had hepatitis, 4 had gastroenteri-
tis, 3 had lymph node involvement, 2 had infectious mononu-
cleosis with fever, and 9 were asymptomatic. Eight of the 9
cases of PTLD developed within 24 months, and 5 of these
9 patients died of PTLD. PTLD did not occur in any of the
18 patients who underwent LDLT in the last 2 yr, following
routine EBV viral load monitoring. RSV infection occurred
in 2 patients; one occurred immediately after LDLT and this
patient died of acute respiratory distress syndrome.
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Microorganisms No. of isolates (%)
Aerobic Gram-positive 33 (45)
Coagulase negative Staphylococcus 11 (15)
Enterococcus faecium 7 (10)
Staphylococcus epidermidis 5 (7)
Staphylococcus aureus 3 (4)
Gram-positive bacilli 2 (3)
Streptococcus pneumoniae 2 (3)
Streptococcus viridans 2 (3)
Enterococcus faecalis 1 (1)
Aerobic Gram-negative 40 (54)
Klebsiella pneumoniae 12 (16)
Pseudomonas aeruginosa 12 (16)
Enterobacter cloacae 7 (10)
Stenotrophomonas maltophilia 4 (5)
Escherichia coli 2 (3)
Citrobacter freundii 2 (3)
Enterobacter aerogenes 1 (1)
Anaerobic organism 1 (1)
Flavobacterium meningosepticum 1 (1)
Total 74  (100)
Table 3. Microorganisms identified in bacterial infections
Type of infection No. of infections (%)
Sepsis 25 (34)
Peritonitis 18 (24)
Cholangitis 16 (21)
Wound infection 5 (7)
Urinary tract infection 5 (7)
Pneumonia 3 (4)
Enteritis 2 (3)
Total 74 (100)
Table 4. Clinical manifestations of bacterial infections
Etiology No. of episode
EBV (Primary 11, Secondary 26) 37
PTLD 9
Hepatitis 21
Gastroenteritis 4
Lymphadenitis 3
Infectious mononucleosis 2
Asymptomatic 6
CMV (Primary 14, Secondary 4) 18
Hepatitis 9
Gastroenteritis 2
Pneumonia 2
Asymptomatic 7
Rotavirus 10
Enterovirus 2
Rubella virus 2
Respiratory syncytial virus 2
Herpes simplex virus 1
Influenza virus 1
Parainfluenza virus 1
Table 5. Causes of viral infections
EBV, Epstein-Barr virus; PTLD, posttransplant lymphoproliferative dis-
ease; CMV, cytomegalovirus.Cause of death after LDLT
Of the 95 patients, 80 (84%) survived. Of the 15 deaths,
7 were associated with viral infection, including 5 from PTLD,
1 from CMV infection, and 1 from RSV infection. No bac-
terial or fungal infections were directly associated with mor-
tality.
DISCUSSION
Studies of infectious complications after pediatric LT are
not common, although one study (14) reported that the inci-
dence of infection after pediatric LT was 1.36 episodes per
patient, a result similar to our finding of 1.57 episodes per
patient. In addition, a recent study that included 2,291 chil-
dren (1) reported that severe infectious complications occurred
in 52% of patients within 15 months after LT.
Most infections occurring within 1 month after LT have
been found to be bacterial (7, 9, 15, 16). Bacterial infections
occurring soon after LT have not been associated with increas-
ed mortality (17). Patients undergoing transplantation of
other solid organs, using similar immunosuppressive regi-
mens, showed similar patterns of infectious complications
relative to the interval after transplantation (9). While most
infections during the first month after transplantation are
associated with perioperative problems, those occurring 1 to
6 months after transplantation are associated with the use of
immunosuppressive drugs (18). Most CMV infections occur
between 3 and 8 weeks after transplantation (3, 4, 19), where-
as most EBV infections occur within 6 months. Infections
are relatively uncommon after 6 months and those that occur
are primarily associated with chronic rejection, retransplan-
tation, or large doses of immunosuppressive therapy. We ob-
served similar findings after pediatric LDLT, in that 57% of
bacterial infections occurred within 1 month and PTLD asso-
ciated with EBV occurred more frequently after 6 months. 
We found a similar incidence of infection with Gram posi-
tive and Gram negative organisms, whereas others (14) have
reported that the incidence of infection with Gram positive
bacteria was much higher (78%). We found that the most
common Gram positive infection was with coagulase nega-
tive Staphylococcus, whereas the most common Gram negative
bacteria were enteric bacteria such as Klebsiella pneumoniae,
Enterobacter cloacae, Proteus mirabilis, E. coli, and Citrobacter fre-
undii, findings similar to those of other studies (15, 18). Enter-
ic Gram negative bacteria frequently cause infections in pati-
ents who undergo transplantation of abdominal organs, because
these bacteria can cause peritonitis by spillage from the intesti-
nal lumen into the peritoneum, as well as causing ascending
cholangitis by reflux from the intestinal lumen into the bile
duct during surgery (3, 20-22). Therefore preoperative selec-
tive bowel decontamination and careful attention during sur-
gery are necessary to decrease the rate of infection. Candida
albicans was the only source of fungal infection in our study,
occurring in only two patients. While fungal infection usu-
ally occurs during the third week after transplantation (8),
both cases of fungal infection observed here occurred earlier,
around 10 days after LDLT. However, both were associated
with prolonged preoperative antibiotic usage for prophylax-
is of bacterial infection.
Bacterial and viral infection is an important cause of mor-
tality after LT (1), with CMV reported to be the main source
of viral infection (14). We also found that the infection was the
main cause of mortality after LDLT, with 50% of the deaths
we observed associated with infection. All of these deaths were
associated with viral infection; none was directly related to
bacterial infection. Only one patient died of CMV infection,
which may have been associated with the relatively lower
incidence of seronegative recipients (18 of 88 recipients, 20%,
unpublished data). Of the other deaths, 5 were from PTLD
and one was from RSV infection.
Early detection of EBV infection by quantitative EBV load
monitoring and subsequent reduction in the use of immuno-
suppressive agents has been reported to reduce the develop-
ment of PTLD and mortality (23). We found that the inci-
dence of PTLD decreased dramatically after adoption of EBV
load monitoring. However, our institution has used the lat-
ter routinely only for 2 yr. Further study, for a longer period
of time, is needed.
In conclusion, this study showed that infectious compli-
cations after pediatric LDLT were similar to those observed
after pediatric cadaver donor liver transplantation. While
bacterial infection occurs mainly during the immediate post-
operative period and does not affect patient mortality, viral
infection occurs mainly after 1 month and is a main cause of
patient death after pediatric LDLT. Appropriate attention
should be paid to reduce the morbidity and mortality from
infectious complication according to the period of time after
pediatric LDLT.
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